Neuphoria Therapeutics Inc. (NEUP) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, NEUP carries an RQD Score of 31 and a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The score is the sum of five pillars, each scored out of 20:

• Fundamental Cash Engine: 8 / 20. The pillar reflects ROIC of -11.8% and an FCF yield of 0.47%. Negative ROIC means the business is not currently earning a return above its cost of capital; the low FCF yield means little cash generation relative to market value.
• Whale 13F Flow: 3 / 20. Institutional accumulation and options positioning scored near the bottom of the range. The source data contains no holder detail (see the Analyst View section), so this pillar's score cannot be traced to specific filings in this dossier.
• Insider Conviction: 5 / 20. Scored on SEC Form 4 and Congressional PTR cluster flow. No individual insider transactions are listed in the source data.
• Macro Regime Fit: 7 / 20. Beta of 1.0 and sector sensitivity are the stated inputs.
• Forensic Balance Sheet: 8 / 20. The pillar cites an Altman Z-Score of 0.2, a Piotroski F-Score of 5/9, and Debt/Equity of 0.5. An Altman Z-Score this low is typically associated with elevated financial-distress risk in the framework that produces it.

For a prospective investor evaluating the stock today, the rating points to weak fundamentals, weak institutional and insider support signals, and a fragile balance sheet. Upside drivers would have to come from a change in the underlying cash-generation profile, which the reported figures do not yet show. The rating does not establish a price target or a specific timeline, and it should be weighed against the fact that several inputs (valuation multiples, analyst coverage, holder data) are unavailable in the source data.

Per the SEC financials, FY 2025 shows revenue of $15.6M with a net loss narrowing to $-0.4M and positive FCF of $0.1M, compared with revenue of $0.0M and net losses of $-15.5M in FY 2024. Per the market data, the operating margin is -7.2%, the net margin is -2.4%, and the gross margin is 0%, with ROIC at -11.8%. The Altman Z-Score of 0.2 and Piotroski F-Score of 5/9 are cited in the Roarable RQD rating, and Debt/Equity of 0.5 is also cited there; the balance sheet debt line in the financials is N/A, so the source does not independently confirm the debt level. Cash rose to $22.2M in FY 2025 from $4.3M in FY 2024.

• Rights agreement extension (RED/YELLOW context): Per the news wire, Neuphoria extended the expiration of its rights agreement to October 2027, reported by Investing.com.
• Risk Watch item: A Risk Watch-tagged item (RED light) from a siam.in-sourced report describes a -0.83% move on 2026-10-23 and questions where price support lies. No further detail is provided.
• Market wire items: Several YELLOW-light market wire items from Yahoo! Finance Canada, TradingKey, and a seasonal chart feed reference NEUP in market-action coverage. These carry no company-specific fundamental content in the source text.
• Proprietary signals: None listed in the Butterfly Supply-Chain Graph.

• What products or therapies does Neuphoria commercialize, and what is the source of its $15.6M FY 2025 revenue?
• What drove the swing from net loss of $-15.5M in FY 2024 to a net loss of $-0.4M in FY 2025, and is the $0.1M FCF repeatable?
• What is the reported debt level, given the financials list debt as N/A while the RQD rating cites Debt/Equity of 0.5?
• What are the terms and purpose of the rights agreement extension, and does it carry dilution implications?
• Why is the FY 2025 cash balance of $22.2M not reconciled to the FY 2024 figure of $4.3M in the source data, and what is the cash runway at current burn?